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CaliforniaABSTRACT Congenital and acquired (drug-induced) forms of the human long-QT syndrome are associated with alterations in
Kv11.1 (hERG) channel-controlled repolarizing IKr currents of cardiac action potentials. A mandatory drug screen implemented
by many countries led to a discovery of a large group of small molecules that can activate hERG currents and thus may act as
potent antiarrhythmic agents. Despite significant progress in identification of channel activators, little is known about their mech-
anism of action. A combination of electrophysiological studies with molecular and kinetic modeling was used to examine the
mechanism of a model activator (NS1643) action on the hERG channel and its L529I mutant. The L529I mutant has gating
dynamics similar to that of wild-type while its response to application of NS1643 is markedly different. We propose a mechanism
compatible with experiments in which the model activator binds to the closed (C3) and open states (O). We suggest that
NS1643 is affecting early gating transitions, probably during movements of the voltage sensor that precede the opening of
the activation gate.INTRODUCTIONThe human ether-a`-go-go-related gene 1 (hERG1a), also
referred to as the KCNH2 gene, encodes a voltage-activated
potassium channel (Kv11.1). This ion channel, simply de-
noted as ‘‘hERG’’, plays a crucial role in the delayed recti-
fied potassium current (IKr) in cardiac myocytes (1–3).
Although the overall structure of hERG is homologous to
that of other potassium channels, its gating kinetics is
distinct and is characterized by a comparatively slow activa-
tion and deactivation kinetics (on the order of hundreds of
milliseconds to seconds) but very rapid, voltage-dependent
inactivation (on the order of milliseconds to tens of millisec-
onds) (2,4,5). It is generally agreed that gating dynamics of
hERG is essential for its function in the cardiac repolariza-
tion process. In the ascending phase of the action potential,
as a result of slow activation and simultaneous fast inactiva-
tion, little outward current flows through hERG during de-
polarization. As the membrane repolarizes, the channels
recover from inactivation much faster than they deactivate,
generating an outward current that is the key determinant
for the termination of the plateau phase of the action poten-
tial (4). Congenital mutations or drug binding that perturbs
hERG currents may have both therapeutic and proarrhyth-
mic consequences (6–9). An implemented screen of novel
drug candidates for potential to attenuate hERG functionSubmitted April 17, 2014, and accepted for publication December 8, 2014.
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0006-3495/15/03/1414/11 $2.00has led to identification of compounds capable of hERG cur-
rent enhancement (2). However, a thorough examination of
the effects of hERG activators in vitro and in intact cardiac
tissue has not yet been performed.
A drug-induced increase in the time-dependent IKr rather
than its tail current can truncate the action potential and cause
the short QT syndrome, similar to that of gain-of-function
mutations (10). The short QT syndrome results from
decreased inactivation leading in an increase in time-depen-
dent current at the expense of loss of inward rectification, its
negative slope conductance, and a decrease in tail current
amplitude (relative to time-dependent current). Similarly,
hERG activator drugs, which shift C-type inactivation, could
be proarrhythmic or antiarrhythmic, depending on the details
of their effect on action potential duration and its shape. For
example, some activators maintain inward rectification and
increase the tail current, whereas others shift the voltage-
dependence of C-type inactivation to depolarized potentials
and thus increase the time-dependent current at the expense
of decreasing the tail current amplitude (2). The key to better
understanding of safe drug design is to analyze, at the molec-
ular level, their action mechanism to have a clear goal of
increasing tail currents without an increase in the time-
dependent current, and then to iteratively refinemodel/exper-
iment to generate safe and effective drugs.While a number of
groups have identified molecular pockets responsible for
interactions with a range of hERG activators (11–14), it is
unclear how drug binding perturbs IKr and which of the states
in channel gating is stabilized by binding of an opener.http://dx.doi.org/10.1016/j.bpj.2014.12.056
Kinetic Model of NS1643 Action on WT hERG and L529I Mutant 1415In a 2012 study, Durdagi et al. (12) used structure-guided
mutagenesis strategy and voltage-clamp assays to identify a
number of novel amino acids that frame the binding pocket
for a model hERG activator NS1643 (1,3-bis-(2-hydroxy-5-
trifluoromethyl-phenyl)urea) shown in Fig. 1. One of the
amino acids identified but not examined in that study was
L529 (Fig. 1), which corresponds to known hydrophobic-
switch isoleucine in the ILT domain described by the
Aldrich laboratory (15,16). Further studies combining mo-
lecular modeling, biophysical and electrophysiological re-
cordings for wild-type (WT) WT-hERG, and a set of
L/X529 mutants (14) provided direct evidence for a possible
coupling between an activator binding site around L529
(Fig. 1) and gating kinetics. We also found that before appli-
cation of NS1643, the activation characteristics of WTand a
conservative mutant (L529I) channel are similar. However,
after application of NS1643, the slope of the activation
curve in the L529I variant of hERG channel flattened signif-
icantly. This is indicative of reduced voltage sensitivity in
the mutant. To reveal detailed mechanism of drug action,
it is necessary to understand which steps in channel activa-
tion dynamics are perturbed. Several kinetic models are
available that can account for hERG gating kinetics (17–
19). Despite these studies, understanding of hERG activa-
tion gating lacks the depth of that for Shaker channels and
this places significant limits on the mechanistic interpreta-
tion of electrophysiological and pharmacological data on
activator mechanism of action. Accordingly, this study de-
velops a kinetic model to explain mechanism of NS1643
attenuation of IKr in WT and L529I mutants of the hERG
channel—two systems with marked differences in drug-
dependent activation dynamics. We combined electrophysi-
ological measurements with mathematical modeling to gain
deeper understanding of functional factors governing acti-
vator action in hERG channels.FIGURE 1 hERG open state homology model (pore domain and voltage
sensor domain (VSD)). Proposed binding region for NS1643 in the vicinity
of L529 is highlighted (blue, left). Chemical structure of NS1643 drug (top
right). (Boxed region, left) An expanded and rotated view of one VSD sub-
unit highlighting the mutation location in S4 helix. To see this figure in co-
lor, go online.MATERIALS AND METHODS
Experimental methods
Molecular biology
The methods for site-directed mutagenesis have been previously reported in
Durdagi et al. (12). The hERG1a constructs were transfected into mamma-
lian hEK cells because their background potassium currents are small and
no dofetilide-sensitive tail current is observed in untransfected hEK cells.
The mutant L529I construct was generated with conventional overlap
PCR using primers synthesized by Sigma Genosys (Oakville, Ontario,
Canada) and sequenced using a Eurofins MWG Operon (Huntsville, AL).
Constructs were linearized with XbaI restriction endonuclease and cRNA
was transcribed in vitro using the mMessage mMachine T7 Ultra cRNA
transcription kit (Ambion, Austin, TX).
Electrophysiology
Transfected hEK cells were grown on glass coverslips. The coverslips were
placed in a 2 cc chamber, which was superfused at a rate of 2 mL/min at
room temperature. The whole-cell voltage-clamp methods have been previ-
ously reported in Durdagi et al. (12). The pipette solution contained KCl
10 mM, K-aspartate 110 mM, MgCl2 5 mM, Na2 ATP 5 mM, EGTA
10 mM, HEPES 5 mM, and CaCl2 1 mM, corrected to pH 7.2 with KOH.
The extracellular solution contained NaCl 140 mM, KCl 5.4 mM, CaCl2
1 mM, MgCl2 1 mM, HEPES 5 mM, and glucose 5.5 mM, corrected to
pH 7.4 with NaOH. For IKr measurements, the whole cell configuration
of the patch-clamp method was used. The series resistance measured in
the solution was <7 MU. Data were sampled at 1 kHz. The holding poten-
tial was 80 mV. All tail currents reported in this article represent dofeti-
lide-sensitive currents. The NS1643 (Tocris Bioscience, Ellisville, MO)
was dissolved in DMSO (30 mM) first and then diluted into the extracellular
solution. All the experiments were performed at room temperature. The
data was sampled at 2 kHz and analyzed with the software CLAMPFIT
(Axon Instruments, Molecular Devices, Eugene, OR). Student’s t-test was
used in the statistical analysis.
Voltage dependence of activation. From a holding potential of 80 mV,
cells were depolarized for 1 s to a range of voltages from þ50 to
100 mV in a 10-mV step followed by a step potential to 100 mV for
1 s to record the tail currents. If the tail current did not completely deacti-
vate by100 mV, a120-mV, 1-s prepulse was applied to completely close
the hERG channels before subsequent depolarization. The isochronal tail
current-voltage plots were fit to a single Boltzmann function:
I
Imax
¼ 1
1þ expV1=2  Vk: (1)
In this formulation, V1/2 is voltage of the half-maximal activation, and k is
the slope factor.Inactivation V0.3 parameter. The inactivation of hERG was measured by
a previously reported triple-pulse protocol (12). The holding potential was
80 mV. The hERG channel was first depolarized to þ50 mV for 500 ms.
Recovery from inactivation was achieved using a short pulse (5 ms hyper-
polarization) to120 mV, followed by application of test pulses from100
to þ60 mV for 1 s in 10-mV steps. The inactivation ratio was measured as
the ratio of the tail current level at 50 ms after onset of the test pulses over
the theoretic peak tail amplitude, which was calculated by back-extrapo-
lating the linear portion of the peak tail current. The inactivation ratio
was plotted against the voltage of the test pulses.
To resolve the time-course of inactivation from deactivation, we chose to
examine inactivation at voltages wherein the time-constants of deactivation
and inactivation were most different. At the beginning of the third pulse, the
hERG channels are mainly recovered from inactivation and in an open state.
Thereafter, hERG currents simultaneously begin to deactivate and inacti-
vate, depending on membrane potential. At potentials negative to EK, the
current deactivates very rapidly. Even at voltages of 70 to 60 mV theBiophysical Journal 108(6) 1414–1424
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tion. To minimize the contribution of contamination by deactivation, we as-
sessed the V0.3, a voltage where inactivation dominates. To extract a
parameter to represent the voltage-dependence of inactivation (with little
contamination of deactivation) in a large number of mutations channels,
we used the V0.3 measurement. Another parallel measurement of the
voltage-dependence of inactivation was used to validate the V0.3 metric of
inactivation. The t of inactivation process was plotted against voltage.
Both measurements of voltage-dependence of inactivation are accurately
parallel to each other.
Fast component of deactivation. Deactivation of hERG tail current was
measured at 100 mV. To simplify the evaluation of the effect of
NS1643, the tail current at 100 mV was fitted to the single exponential
function,
I ¼ Imaxe tt þ C;
in which t is the characteristic time constant. A single exponential function
fitted the tail current well. The coefficient of determination for the fit ranged
from 0.98 to 0.99. Tail currents recorded at 50 mV are best fit to a biex-
ponential model; accordingly, tail currents in this study were recorded at
100 mV, where deactivation can be adjusted to a single exponential (3).
Statistical analysis. The software STATSVIEW (Abacus Concepts, Ber-
keley, CA) was used to analyze the data. Data are presented as mean 5
SE. An unpaired Student’s t-test was used to compare data, with a two-
tailed P-value of 0.05 designated as being significant.Modeling
Awell-established five-state Markov model was used to describe gating of
the WT-hERG channel (17,18). Electrophysiological measurements were
used to fit the model rate constant parameters to account for the effects
of a single point mutation (L529I) and drug application to WT and mutant
forms of the hERG channel. In this study, the model parameters for the
L529I mutant of hERG channel were obtained by fitting the respective aver-
aged measured experimental data for deactivation (corresponding time con-
stants), steady-state activation curve (V1/2 and k), and inactivation voltage
relationships at 0.3 (V0.3).
WT hERG kinetic model
Kinetic modeling of hERG channels has a long history with several gating
schemes proposed to date (18). Virtually all of them operate on the assump-
tion of Markovian behavior in gating dynamics of hERG channels. The
simplest and most accepted Markov model for WT-hERG in Wang et al.
(17), is shown in Fig. 2. In this kinetic model of hERG, the terms Cx, O,
and I represent closed states, open states, and inactivated states, respectively
(x ¼ 1, 2, or 3). The transitions between C2 / C1 and C1 / C2 are
voltage-independent processes (ain and bin). The others are voltage-depen-
dent transitions (ae, be, aa, bb, bi, and ai).
This model implies three closed (nonconducting) states and introduces a
voltage-insensitive transition required to account for activation. Several
lines of experimental studies showed that there is a possible transition be-
tween the closed directly to inactivated state (20,21) and therefore the
original Rasmusson model from Wang et al. (17) is incomplete. However,
in all these models transitions between closed and inactivated states
are assumed to be a low probability transition and thus considered negli-
gible (22).FIGURE 2 Proposed kinetic mechanism for WT hERG (17) showing the
transition rates labels used in this work.
Biophysical Journal 108(6) 1414–1424The IKr current is given by the equations
IKr ¼ gKrpOðV  EkÞ (2)
and
gKr¼ g
0
KrðaT þ bÞ
 
½Kþ0
5:4 mM
!1
2
; (3)
where gKr
0 ¼ 0.024 pA/pF/mV, a ¼ 1/35 K1, b ¼ 55/7, and pO is the
open probability resulting from the model above. State probabilities are
found by solving the first-order differential equations system that corre-
sponds to the kinetics mechanism shown in Fig. 2.
Rate constants formulation
If a kinetic network with several states is considered, then the transition
rates (k) corresponding to the transition i between pairwise states of the sys-
tem can be written in Eyring-like kinetic relationships (23,24) to describe
hERG gating,
ki ¼ koe
DGiðVÞ
RT (4)
or
ki ¼ kBT
h
e
DSi
R 
DHi
RT þ
ziFV
RT ; (5)
where T is the absolute temperature, V is the voltage across the membrane,
DS is the change in entropy,DH is the change in enthalpy, and zi is the effec-
tive valence of moving charges.
This type of model assumes that the gating of ion channels operates
through successive conformational changes of the protein. The rate of the
transition depends exponentially on the free energy barrier between the
states.
According to this linear thermodynamic model, the free energy change of
the transition i can be written as
DGiðVÞ ¼ Ai þ BiV; (6)
whereAi ¼ DHi  TDSi;
Bi ¼ DziF:The constant Ai corresponds to the free energy that is independent of the
electric potential, and the linear term BiV encompasses the effect of the
external electrical potential on the system.
The transition rate (ki) in Eq. 5 can be rewritten in a simplified form as
ki ¼ aiebiV ; (7)
where
ai ¼ kBT
h
e
DSi
R 
DHi
RT

ms1

;
ziF  1bi ¼ RT mV ;
and V is the external electric potential in millivolts.
Kinetic Model of NS1643 Action on WT hERG and L529I Mutant 1417The simple exponential voltage dependence of rate constants is often
referred to as the linear thermodynamic model (25). Nonlinear thermody-
namic models of different complexity are described in the literature to fit
voltage-clamp data, especially in cases where linear models fail to ac-
count for activation kinetics. The rate constant for each step was previ-
ously derived by Fink et al. (25) using the latest comprehensive
experimental data from Berecki et al. (26). The parameters were derived
using data from hEK cells at room temperature and 37C. The tempera-
ture dependence of hERG was modeled using data available from the
literature for Q10 values for the various time constants based on
voltage-step protocols (27). In this study, all the rate constants, extracted
from the previous model (25), were used as initial guess values. Correc-
tion to individual parameters from Fink’s article (25) has been done to
reproduce our hEK-cell measurements at room temperature (23C). All
fitted parameters for the kinetic mechanism considered can be found in
Table 1 and Table S1 in the Supporting Material. Note that b was set
to zero for transition rates ain and bin (Fig. 2), thus, these transitions
are modeled as voltage-independent (17,27). The transitions between O
and I are also dependent on extracellular potassium concentration
[Kþ]0 (28). That dependence is accounted for by modifying the transition
rate for inactivation (O / I, bi):
kbi

Kþ
0 ¼ k0bi
 
5:4 mM
½Kþ0
!0:4
: (8)
Optimization procedure
The model parameters were optimized to reproduce macroscopic currents
guided by the data recorded at room temperature for hEK cells. All compu-
tations were done using two approaches that allow simultaneous optimiza-
tion of different numbers of voltage-clamp (VC) protocols.
1. MATLAB (R2011a) and C/Cþþ code. The optimization algorithm used
is the FMINSEARCH MATLAB function (Nelder Mead Simplex
method) with bound constraints by transformation.
2. A Cþþ code developed with parallel capabilities. The optimization al-
gorithm used is PRAXIS (29) with constraints.
In both cases, differential equations from the Markov model are solved
numerically by the Runge-Kutta algorithm (fourth order, with an integra-
tion time step of 0.01 ms). The VC step protocols are coded to match
the voltage-time function from the experimental protocol (details in
the Supporting Material). The total cost function (F) is defined as the
summation of n partial cost functions (fi) obtained from each VC proto-
col (Eq. 9), where n is the number of protocols considered, x1,.,xm areTABLE 1 Parameters (Eq. 11) optimized at room temperature for W
Rasmusson kinetic model from Wang et al. (17)
Transition description Label
WT
a (ms1) b (mV1)
C3/ C2 ae 0.0867 0.0212 2
C2/ C3 be 0.0360 0.0734 1
C2/ C1 ain 0.0102 — 0
C1/ C2 bin 0.0299 — 1
C1/ O aa 0.0116 0.0438 6
O/ C1 bb 0.000136 0.0418 1
O/ I bi 0.125 0.0231 0
I/ O ai 0.00364 0.0327 1
F value 2.83  106
Experimental data obtained from hEK cells at room temperature. Underlined nthe parameters to be adjusted, and m is the total number of parameters
considered:
F ¼
Xn
i¼ 1
fiðx1;.; xmÞ: (9)
The term fi is computed as the mean-square deviation of the simulated and
experimental data. This relation is shown in Eq. 10, where l is the number ofdata points considered and y is the absolute experimental or simulated value
considered:
fiðx1;.; xmÞ ¼ 1
l
Xl
j¼ 1

ysimj  yexpj
2
: (10)
The total cost function is then minimized using the optimization algorithm
by varying the kinetic parameters until converged to a given value of
tolerance.
We performed a convergence analysis on the cost function (F) and all its
terms (fi) (Eq. 10). The analysis consisted in the numerical computation of
the first and second derivatives of F and fi as a function of all adjusted pa-
rameters (x1,.,xm). The procedure involved the computation of a vector
and a matrix. The vector was constructed by computing all the cost func-
tions while varying by 0.01 each parameter around the optimized value.
In the same way, the matrix was built by changing two parameters at a
time. Subsequently, a system of linear equations was solved to obtain the
parameters for a second-order Taylor polynomial of several variables.
The first derivative terms account for the convergence of the cost function
for each parameter. The self-second derivative terms provides information
about the sensitivity of the cost functions to each parameter. The cross-sec-
ond derivative terms account for the dependence of pairwise parameters and
can be used to distinguish redundant parameters. All these terms together
provides information about the completeness of the experimental data set
to be univocally described by the kinetic parameters of the proposed test
mechanism.
Wild-type. Simulated steady-state activation curve and deactivation time-
course closely fit the observed experimental data for WT using both codes
(Table S1 and Fig. S1 in the Supporting Material). The hybrid MATLAB/C
code uses the same optimization algorithm that was used in Fink et al. (25)
(with the Nelder Mead Simplex method), while the Cþþ code uses a
different one (PRAXIS). The total cost function minimization seems to
be improved with the second one. The parallel capability of the optimized
pure Cþþ code allows for faster minimization procedures. Table 1 shows
the corrected a- and b-parameters for WT rate constants according to
Eq. 7. Despite some differences in the initial parameters, the simulated
and measured currents are in excellent agreement (see current traces in
Fig. 4). It is important to note that the parameter set is not unique butT (all unconstrained) and L529I-hERG (Set A) using the
L529I Fitting set
a b
A B C
a b a b a b
.13 1.00 U F U F F F
.02 0.62 U U U F F F
.61 1.00 U — U — F —
.03 1.00 U — U — F —
.00 1.17 U U U F U F
.23 1.00 U F U F U F
.90 1.00 U F U F U F
.05 1.00 U F U F F F
4.67  106
umbers are fixed values. U, unconstrained; F, fixed.
Biophysical Journal 108(6) 1414–1424
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diverse data training set ensures a robust set of parameters sufficient for ac-
curate description of hERG gating in good accord with previous studies
(18,23). Sensitivity and convergence analysis was done for the fitting. We
found that all parameters were well converged except for the parameters
associated with the deactivation rate (4). The sensitivity of the cost function
to this parameter is low compared to the rest, which may indicate that addi-
tional data is required to improve the convergence of this step.
L529I and NS1643 effect. A group of different fit results was obtained by
using a diverse set of constrained and unconstrained parameters during the
optimization procedure. The purpose of this strategy is to identify the min-
imal key parameters required to reproduce the experimental behavior. The
cost function absolute value and the sensitivity of the function to each
parameter for every VC protocol were monitored to assess the success of
the fit. From the group of different fit results, the best three sets of con-
strained and unconstrained parameters (A, B, and C) were selected (Table 1)
and shown together with F. The effect of the drug and mutation were eval-
uated by introducing two correction terms, a and b, to a- and b-parameters,
respectively (Eq. 11). During the optimization, a and b were set constant,
and a and b were varied:
ki ¼ aiaiebibiV : (11)
For the effect of the drug, a new kinetic mechanism was proposed and eval-
uated during the fit. In this explicit modeling of the drug, rates constantsinvolved with the states without the drug were fixed for WT and for
L529I (rates in Table 1). The drug binding kon and koff were constrained
by the upper- and lower-bound experimental estimates of the equilibrium
dissociation constant (Kd) to the open and closed states of the channel.
The experimental values of Kd are in the range of 1–20 mM (30,31); these
values may reflect a weighted average of the affinity for the closed and
open states dependent on the relative rates of transitions between the states
and the drug binding and unbinding rates. Different values for Kd-Open
and Kd-Closed in the range of the experimental findings were tested. kon
(mM1 ms1) for open and closed states were set at the same guessed value
and constrained to a range of 0.5  102 to 5.0; koff (ms1) values for open
and closed states were constrained by Kd-Open and Kd-Open, respectively. The
selected fits contain the minimum number of parameters needed to achieve
the best F value.RESULTS AND DISCUSSION
In vitro electrophysiology results
Ion currents conducted by WT hERG and L529I-hERG
channels expressed in hEK cells were recorded using the
voltage-clamp protocols described in the Materials and
Methods. The detailed experimental evaluation of WT
and L529I gating kinetics are published by our group in a
companion article (14). The effects of the drug NS1643
on the hERG channel and L529I mutant using the steady-
state activation protocol are shown in Fig. 3. In both cases,
the drug application caused an increase in the magnitude of
the tail current, a left shift in the voltage dependence of
activation for WT, and a substantial slope decrease in the
case of the mutant without shifting the V1/2. A right-shift
of the inactivation curve (measured as V0.3) and a slowing
of fast component of deactivation t (predominant compo-
nent at 100 mV) was found for both WT and mutant (3)
(Table 2).
Concentration-response relationships for tail current
amplitude and deactivation were found to have a biphasicBiophysical Journal 108(6) 1414–1424nature in a previous study (12). This is in agreement with
the proposed dual-mode of action for other channel activa-
tors (11), which may act as blockers at high concentra-
tions. The biphasic nature of the concentration-response
relationships found for NS1643 makes rigorous experi-
mental fitting problematic. In all the subsequent in vitro
studies, a drug concentration of 10 mM was used. This
test concentration produces markedly evident changes in
the electrophysiological metrics considered in this study
(Table 2).Kinetic modeling of WT and L529I
We initially fitted the kinetic model used for WT hERG
(Fig. 2) to the experimental data. All transition rates were
written using Eq. 7. Fink’s values for a- and b-parameters
were used as an initial guess. Parameters were varied until
Fwas minimized. At this point, the simulated observed rates
of deactivation, the steady-state activation parameters, and
the V0.3 value of WT matched the experimental data.
Fig. 4 and Fig. S1 show that the current traces, the simulated
steady-state activation curve, and deactivation time course
closely fit the observed experimental data for WT. We
next investigated whether this model could be extended to
assess the gating measurements for the L529I mutant.
Table 1 shows the best fit obtained for WTand L529I. Other
optimizations resulting from different combinations of con-
strained and unconstrained parameters are shown in
Table S2.
As already mentioned in Materials and Methods, three
different arrangements of constrained and unconstrained pa-
rameters (A–C) were selected (Table 1) and shown in Fig. 5.
As it can be seen from Table S2, the quality of the fit is
slightly increased when some of the voltage-dependent pa-
rameters are allowed to vary, especially the transition rate
‘‘be’’ (A). Similar fit quality could also be obtained keeping
fixed all voltage-dependent parameters (B), suggesting that
the transition’s voltage dependence is almost the same as
that of the WT. Set C shows that fixing the closed state tran-
sition reduces the quality of the fit. Simulated current traces
at 0 and 20 mV show an increase in the current tail ampli-
tude, compared to WT, and a slightly faster decay for deac-
tivation at 100 mV (Fig. 5).
According to set A (best fit), the modeling suggests that
L529I mutation increases activation rates (steps ae, aa).
This mutation appears to slightly reduce the inactivation
rate while not affecting recovery from inactivation. The
voltage-insensitive steps seem to be slightly affected, and
a very good fit could be obtained by keeping them fixed
(Table S2 and Set B in Table 1).
Taking all data together, these results suggest that the
L529I mutant stabilizes an open state of the channel by
mainly increasing activation rates, slightly affecting the
voltage insensitive steps, and without affecting the voltage
dependence of the transitions to the open state.
A B
FIGURE 3 Experimental characterization of the
effects of NS1643 on the voltage dependence of
activation for WTand L529I mutant hERG channel
expressed in hEK cells at room temperature.
(A) Representative current traces elicited by the
voltage-clamp protocol depicted (top) for both
WT and the L529I mutant, and the control and
NS1643 effect. (B) Steady-state activation experi-
mental data control/NS1643 (red squares, red
circles, respectively) application (10 mM) for WT
hERG (top) and control/NS1643 (blue squares,
blue circles, respectively) application for L529I
mutant. To see this figure in color, go online.
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and L529I
Experiments show that the NS1643 drug shifts the V1/2 of
activation by 205 6 mV in WT hERG without alteration
of the slope of the current voltage relationship (Fig. 3 B).
The V1/2 of activation of the drug-free L529I hERG is
similar to the WT with drug. However, after adding the
drug, the slope of the current-voltage relationship is signif-
icantly and substantially flattened while the V1/2 is almost
unchanged. Experimental data indicate that NS1643 signif-
icantly alters a transition in the pathway to activation in
L529I (Fig. 3 B, bottom).
There are limited data available about the NS1643 bind-
ing to hERG (2,31). These data come from site-directed
mutagenesis, voltage-clamp assays, and molecular
modeling using homology models. The binding site on
hERG was proposed previously to be located on the outside
of the channel based on several findings (31). Grunnet et al.
(32) used a homology model of the channel pore and pro-
posed a site located within S5 and S6 of adjacent subunits.
Recently, several lines of evidence implicate the region
formed by residues from interhelical contacts of theTABLE 2 Experimental data for hEK cells at room temperature
Cells Activation V1/2 and k (mV)
WT 12.45 2.3 (n ¼ 10); 8.1 5 0.2 (n ¼ 10)
WT þ NS1643 32.45 3.5 (n ¼ 10); 9.4 5 0.3 (n ¼ 10)
L529I 30.85 2.6 (n ¼ 25); 8.9 5 0.4 (n ¼ 25)
L529I þ NS1643 34.45 3.7 (n ¼ 25); 22.15 1.5 (n ¼ 25)
Each value is an average of n experiments. Equation 1 was used to obtain V1/2voltage-sensor domain (VSD) at the interface between heli-
ces S1, S2, S3, S4, and S5 of the adjacent subunit (33). This
site was partially described and labeled as ‘‘IC2’’ in the pre-
vious study by Durdagi et al. (12) using a homology model
for the open state hERG. It was more carefully explored
recently with the L529I mutant (14) (Fig. 1). To study the
effects of the drug, different models that include two popu-
lations of hERG channels in drug-free and drug-bound
states were considered (Fig. 6). Transition rates between
drug-free states were fixed to previously obtained values
(Table 1). When transition rates of drug-bound states were
fixed, the same drug-free transition rate values from Table 1
are used. Table 3 shows the parameters optimized for the
best fits. Table S3 shows other mechanisms considered,
the effect of changing Kd-Open/Kd-Closed, and the effect of
considering different number of parameters in the fit.
From all the mechanisms tested (Fig. 6), mechanisms M2
or M4 appear to provide the best fit for WT. The mechanism
M4 appears to be, simultaneously, the simplest and the most
accurate (Fig. 7 A). The experimental data can also be fitted
reasonably well to M1 where the drug binds just to the C3
state. However, under this mechanism, unlike the others,V0.3 inactivation (mV) Deactivation, tFast (ms)
25.05 3.5 (n ¼ 6) 129.065 13.3 (n ¼ 9)
18.65 3.7 (n ¼ 6) 263.715 30.7 (n ¼ 9)
22.65 2.9 (n ¼ 11) 104.105 9.6 (n ¼ 18)
12.05 4.3 (n ¼ 11) 189.025 10.3 (n ¼ 18)
and k; data are presented as mean 5 SE.
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A B
FIGURE 4 Simulations after fitting to the experimental data for the two
different voltage-clamp protocols for WT hERG at room temperature.
(A) Voltage protocols (1,2) used in the experiment and coded for simula-
tions. (B) (Top) Superimposed simulated current traces at voltages 50,
40, 30, 20, 0, 20, 30, and 40 mV elicited by voltage-clamp protocol
1 and used to build the steady-state activation curve. (Bottom) Simulated
current traces 25 (up to 50 ms) and 100 mV elicited by voltage-clamp
protocol 2 and used to study the deactivation at 100 mV and V0.3. To
see this figure in color, go online.
FIGURE 6 Kinetic models of hERG channel gating modified by
NS1643. Different Markov models representing populations of hERG chan-
nels in drug-free and drug-bound (highlighted in cyan) states are labeled as
M1–M8. Transitions between the sections were described with an estima-
tion of the equilibrium dissociation constant Kd ¼ koff/kon. Mechanisms
that were able to reproduce the drug’s effects on the kinetics are highlighted
(gray) (M1–M5). To see this figure in color, go online.
1420 Perissinotti et al.the rates for aind and bind are considerably lower. Fig. S2
shows that while M2 and M4 display a similar current trace
for protocol 1 (Fig. 4 A), M1 is quite different. The mecha-
nisms M3 and M5 (Fig. 6) allows a good fit but the quality is
inferior to M2 and M4. To further test how NS1643 is
affecting the early states, we considered mechanisms M6–
M8, where no binding was considered to C3. From these op-
tions, only M6 showed some small success in reproducing
the gating behavior (Fig. 7 A). The other ones were not
able to successfully adjust the experimental data. These re-A B
FIGURE 5 Modeling of L529I hERG mutant. (A) Superimposed
simulated current traces for voltages 0 and 20 mV for WT (red) and
L529I mutant (blue, scheme A). Currents were elicited by voltage-clamp
protocol 1, shown in Fig. 4. (B) Steady-state activation simulated curve
for WT (solid red line) and L529I (sets A, B, and C in solid blue, dotted
gray, and slashed gray lines, respectively). WT and L529I experimental
data (red and blue squares, respectively). To see this figure in color, go
online.
Biophysical Journal 108(6) 1414–1424sults highlight the importance of the drug binding to the
C3/C2 states, although with less affinity compared to the
open state.
In the case of the L529I mutant, the quality of the fit was
worse compared to WT. In this case, obtaining a good fit is
challenging (Table 3). The fit is highly improved by including
the variation of the b-parameters, especially the ones associ-
atedwith the activation and deactivation transitions (Table 3).
In this case, M1–M4 were all able to fairly reproduce the
experimental behavior. It is interesting to note that, in this
case, the model suggests much higher affinity for the closed
state compared to the open (the opposite to WT). Indeed,
M6 showed a very bad fit to the experimental data, pointing
to the fact that binding to early closed states is of key impor-
tance in the case of the L529I mutant. As found for WT, M7
and M8 were not able to fit the experimental data.
Based on this parametric study, we propose that M4 is a
mechanism of choice to rationalize the effect of NS1643
on hERG channel gating (Fig. 8). In this mechanism, we
propose that the NS1643 drug binds to closed (C3 and
C2) and open (O) states but with different affinities
(i.e., the state-dependent binding mode). The parametric
study within the proposed mechanism M4 allows for testing
several ratios and orders of magnitudes for Kd-Open and
Kd-Closed and different number of parameters (Table S3).
In the case of WT, the model suggests that the activator’s
binding affinity for open state seems to be higher than for
the closed state. Importantly, for L529I, most of the
voltage-dependent parameters were reduced and the non-
voltage-dependent rates (ain and bin) were considerably
diminished. In this case, activator-binding affinity seems
to be much higher for the closed state and higher compared
to WT. However, the binding affinity for the open state
seems to be lower compared to WT. While experimental
data on activator-state-dependent binding to WT and
TABLE 3 Correction to WT and L529I a, b-parameters obtained after the fitting procedure for NS1643 effect using the different
mechanisms depicted in Fig. 6
Transition description Label
M1 M2 M3 M4
a b a b a b a b
WT þ NS1643
C3D/ C2D aed 1.54 1.00 0.76 1.00 1.62 1.00 1.02 1.00
C2D/ C3D bed 0.36 1.00 0.055 1.00 0.22 1.00 0.15 1.00
C2D/ C1D aind 0.32 — 1.66 — 1.39 — 1.51 —
C1D/ C2D bind 0.083 — 1.13 — 1.09 — 1.00 —
C1D/ OD aad 2.30 0.59 1.32 0.39 1.32 0.61 1.36 0.59
OD/ C1D bbd 0.71 1.00 0.48 1.00 0.42 1.00 0.43 1.00
OD/ ID bid 0.62 1.00 0.61 1.00 0.61 1.00 0.61 1.00
ID/ OD aid 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
O þ D/ OD kon_Oa — 4.4  101 3.20  101 1.00  102
C þ D/ CD kon_Ca 2.44 1.1  101 9.70101 1.00  102
OD4 O þ D Kd_Ob — 3.07 3.11 3.05
CD4 C þ D Kd_Cb 9.46 7.06 12.6 6.25
F value 1.43  105 1.55  106 2.76  105 2.74  106
L529I þ NS1643
C3D/ C2D aed 0.79 1.14 9.9 0.57 4.71 0.78 6.47 0.61
C2D/ C3D bed 0.42 4.13  108 1.49  102 1.10 6.73  103 0.96 1.27  105 1.50
C2D/ C1D aind 0.16 — 0.15 — 0.28 — 0.16 —
C1D/ C2D bind 0.45 — 0.69 — 0.76 — 1.06 —
C1D/ OD aad 1.00 0.71 0.56 0.56 0.48 0.65 1.83 0.52
OD/ C1D bbd 0.81 0.90 0.81 0.85 0.76 0.83 0.81 0.83
OD/ ID bid 0.60 1.00 0.56 1.00 0.55 1.00 0.56 1.00
ID/ OD aid 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
O þ D/ OD kon_Oa — 1.00  102 1.17  102 1.01  102
C þ D/ CD kon_Ca 1.00  102 1.00  102 1.06  102 1.00  102
OD4 O þ D Kd_Ob — 9.76 10.12 9.94
CD4 C þ D Kd_Cb 2.53 1.34 0.075 2.21
F value 4.10  104 2.57  104 2.41  104 1.28  104
Experimental data obtained from hEK cells at room temperature. Underlined numbers are fixed values. Kd_C and kon_C are assumed to be the same for all
closed states.
aUnits in mM1 ms1.
bUnits in mM.
Kinetic Model of NS1643 Action on WT hERG and L529I Mutant 1421L529I hERG is unavailable, the kinetic analysis on the per-
formed experiments suggests that the L529I mutation results
in a higher affinity for NS1643 binding to the closed state,
but not for the open one.CONCLUSIONS
There are a few studies about the mechanism of action of
NS1643. Casis et al. (11) reported that NS1643 activates
hERG channels expressed in Xenopus oocytes in a concen-
tration- and voltage-dependent manner and strongly affects
channel inactivation by shifting the voltage-inactivation
curve by þ35 mV at 30 mM. They also found that NS1643
binding produced minimal effects on the activation of the
channel. However, Durdagi et al. (12) and Xu et al. (31),
in agreement with this work, report that NS1643 can also
left-shift the voltage-dependent activation curve and re-
ported a lower effect on inactivation, depending on the
drug concentration.
Here, we propose a kinetic model for the effects of
NS1643 using our recently published experimental and mo-lecular modeling data for WT hERG and L529I mutant (14).
In that work, experimental data from voltage-clamp fluorim-
etry and biophysical experiments, together with molecular
modeling, is provided. These data suggest that the presence
of NS1643 within its binding pocket alters mainly activation
and deactivation gating of hERG channels by directly modi-
fying voltage-sensor transitions. From a structural point of
view, L529I mutation affects the packing of the VSD of
hERG, probably destabilizing the closed state and favoring
the transition to open state (14). As it can be seen in Fig. 9,
molecular dynamics simulations using the homology
models for open and closed hERG show that the main effect
of the mutation is to change the structure of the S4 helix, re-
sulting in a kink that compromises the VSD packing and
probably affects the NS1643 affinity for the binding site.
Based on these experimental and molecular modeling re-
sults, the major findings of the kinetic modeling can be sum-
marized as follows:
1. The analysis of the experimental data and its interpreta-
tion within a kinetic scheme led to the conclusion that the
L529I mutation leads to a more favorable channelBiophysical Journal 108(6) 1414–1424
AB
FIGURE 7 Simulated steady-state activation curves using the different
mechanisms for the NS1643 effect on WTand the L529I mutant. (A) Simu-
lated curves after fitting to experimental data using different mechanisms
(M1, M2, M3, M4, and M6) for WT. (B) Simulated data after fitting to
experimental data using different mechanisms (M1, M2, M3, M4, and
M6) for L529I. Experimental steady-state activation data for NS1643 effect
is shown in red circles for WT and blue circles for L529I. To see this figure
in color, go online.
1422 Perissinotti et al.opening with minimal effect on the rate’s voltage depen-
dence. This finding is in agreement with the molecular
modeling observation that the kink in the S4 helix pro-
duced as a consequence of the mutation might destabilize
the closed state, favoring the opening of the channel
(Fig. 9).
2. Combined kinetic modeling and experimental data indi-
cate that the activator binding substantially alters the
transitions in the pathway to activation. The modeling
suggests that, in the case of the mutant, voltage depen-
dence of the transitions is strongly compromised together
with the cooperativity on the path to the activation. Our
results on NS1643 indicate that the drug should bind at
least to the closed (C3, C2) and open (O) states of the ki-
netic model, to correctly reproduce experimental data for
both WT and L529I mutant. Therefore, we propose that
NS1643 is affecting early transitions during movementsBiophysical Journal 108(6) 1414–1424of the voltage sensor, which precedes the opening of
the activation gate. In previous modeling works on
WT, NS1634 was suggested to have minimal effect on
the channel kinetics (11,34,35), while another study
modeled the drug as affecting the late activation step
together with inactivation and deactivation (31). Con-
cerning this last study, we tested this possibility in our
fitting schemes (mechanisms M6–M8) without success.
However, including the rates for early activation steps
clearly improved the results for both studied systems.
3. The binding of the NS1643 activator to the mutant chan-
nel results in a dramatic perturbation of the gating ki-
netics. This prediction highlights the importance of the
NS1643 binding site in the neighborhood of the L529
residue, which was reported previously by docking
studies (12). This binding site lies within the interface
between helices S1, S2, S3, S4 (where the mutation
lies), and S5 of the adjacent subunit. Docking calcula-
tions showed three possible binding sites in the vicinity
of L529 for the open state, all of them with almost the
same predicted binding affinity (Figs. 1 and S3). It is
possible that this particular residue may not interact
directly with the drug, but still affect the drug binding
by promoting a change in the binding site due to the
structural change in S4 and the packing of the VSD.
Following this hypothesis, NS1643 may have different
affinity for the site and be able to induce greater confor-
mational change than in WT channels, affecting the
gating properties in a more profound way.
In conclusion, in contrast to a previously suggested mech-
anism of action for NS1643, we propose that the NS1643
activator binds to the early closed states and to the open state
with different affinities. The modeling for the activator ef-
fect of NS1643 on the mutant clearly shows, contrary to
what is observed for WT, that NS1634 is attenuating the
voltage dependence of the transitions to the open state. It
is also affecting the cooperativity of the transitions to
open state and highlighting the importance of this binding
site for future drug designs based on the NS1643 structure
as a template.
The aim of the modeling presented here was to shed light
on the mechanism of action of the NS1643 activator on the
Kv11.1 (hERG) channel. The drug effect on the L529I
mutant provided valuable information on its mechanism of
action and the molecular features of the binding site. We
should emphasize that the modeling done here pertains to
the ion-channel level and is not able to address the antiar-
rhythmic versus proarrhythmic behavior of the NS1643 acti-
vator, which is beyond the scope of this work. However, the
Markovian models presented here for the NS1643 activator
would be of considerable value to study the effect of the
drug at the cellular and tissue levels (36) by using the
available mathematical models for the human cardiac cell
(37,38). Furthermore, these Markovian models provide a
FIGURE 8 Selected simulated current traces for
mechanism M4 for WT (top) and mechanisms M4
and M1 for L529I (bottom). Voltages 40, 20,
and 0 mV were selected from the simulated
steady-state activation curve for WT and L529I
mutant: control (solid line) and NS1643 effect
(dashed lines). Simulated current traces elicited
by voltage-clamp protocol 1 (shown in Fig. 4) at
the selected voltages for the two fits. To see this
figure in color, go online.
Kinetic Model of NS1643 Action on WT hERG and L529I Mutant 1423more detailed alternative than the commonly used Hodgkin-
Huxley formulation of the IKr current.SUPPORTING MATERIAL
Supporting Materials and Methods, Supporting Discussion, four figures,
and four tables are available at http://www.biophysj.org/biophysj/
supplemental/S0006-3495(15)00073-9.FIGURE 9 Effect of the L529I mutation on hERG’s VSD structure. The
S4 helix (in red) structure in WT (top) and the L529I mutant (bottom) in
closed and open states of hERG homology models. Only one hERG subunit
is shown; the S1 segment is omitted for clarity. To see this figure in color, go
online.ACKNOWLEDGMENTS
This work was supported by the Canadian Institutes of Health Research
(grant No. 201103MOP-CSA-244888 to S.Y.N. and H.J.D.), and the Heart
and Stroke Foundation of Alberta (grants No. 2010HSF-2013DUFF and
No. 2011HSF-2014NOSKOV to H.J.D. and S.Y.N.). S.Y.N. is an Alberta
Heritage Foundation for Medical Research Scholar. H.J.D. is an Alberta
Heritage Foundation for Medical Research Medical Scientist. The
computational support for this work was provided by West-Grid Canada
through a resource allocation award to S.Y.N. C.E.C. was supported by
the American Heart Association (GIA grants No. 10GRNT3880050 and
No. 13GRNT14370019),Western States Affiliate; the Alfred P. Sloan Foun-
dation; and the National Institutes of Health (grant No. NHLBI RO1-HL-
085592).REFERENCES
1. Sanguinetti, M. C., C. Jiang, ., M. T. Keating. 1995. A mechanistic
link between an inherited and an acquired cardiac arrhythmia: hERG
encodes the IKr potassium channel. Cell. 81:299–307.
2. Zhou, P. Z., J. Babcock, ., Z. B. Gao. 2011. Activation of human
ether-a`-go-go related gene (hERG) potassium channels by small mol-
ecules. Acta Pharmacol. Sin. 32:781–788.
3. Vandenberg, J. I., M. D. Perry,., A. P. Hill. 2012. hERG Kþ channels:
structure, function, and clinical significance. Physiol. Rev. 92:1393–
1478.
4. Perrin, M. J., R. N. Subbiah,., A. P. Hill. 2008. Human ether-a`-go-go
related gene (hERG) Kþ channels: function and dysfunction. Prog.
Biophys. Mol. Biol. 98:137–148.
5. Vandenberg, J. I., A. M. Torres,., P. W. Kuchel. 2004. The hERG Kþ
channel: progress in understanding the molecular basis of its unusual
gating kinetics. Eur. Biophys. Lett. 33: 468–468.
6. Trudeau, M. C., J. W. Warmke, ., G. A. Robertson. 1995. hERG, a
human inward rectifier in the voltage-gated potassium channel family.
Science. 269:92–95.
7. Numaguchi, H., F. M. Mullins,., J. R. Balser. 2000. Probing the inter-
action between inactivation gating and dd-sotalol block of hERG. Circ.
Res. 87:1012–1018.
8. Clancy, C. E., J. Kurokawa,., R. S. Kass. 2003. Kþ channel structure-
activity relationships and mechanisms of drug-induced QT prolonga-
tion. Annu. Rev. Pharmacol. Toxicol. 43:441–461.
9. Lu, H. R., E. Vlaminckx, ., D. J. Gallacher. 2008. Predicting drug-
induced changes in QT interval and arrhythmias: QT-shortening drugsBiophysical Journal 108(6) 1414–1424
1424 Perissinotti et al.point to gaps in the ICHS7B Guidelines. Br. J. Pharmacol. 154:1427–
1438.
10. Kannankeril, P., D. M. Roden, and D. Darbar. 2010. Drug-induced long
QT syndrome. Pharmacol. Rev. 62:760–781.
11. Casis, O., S. P. Olesen, and M. C. Sanguinetti. 2006. Mechanism of ac-
tion of a novel human ether-a`-go-go-related gene channel activator.
Mol. Pharmacol. 69:658–665.
12. Durdagi, S., J. Guo,., H. J. Duff. 2012. Structure-guided topographic
mapping and mutagenesis to elucidate binding sites for the human
ether-a`-go-go-related gene 1 potassium channel (KCNH2) activator
NS1643. J. Pharmacol. Exp. Ther. 342:441–452.
13. Grunnet, M., R. S. Hansen, and S. P. Olesen. 2008. hERG1 channel ac-
tivators: a new anti-arrhythmic principle. Prog. Biophys. Mol. Biol.
98:347–362.
14. Guo, J., Y. M. Cheng,., H. J. Duff. 2015. An integrated approach to
elucidate the mechanism of action of the hERG (KCNH2) activator,
NS1643: novel binding site at the voltage sensor in the neighborhood
of L529 and K525. Biophys. J. 108:1400–1413.
15. Smith-Maxwell, C. J., J. L. Ledwell, and R. W. Aldrich. 1998. Un-
charged S4 residues and cooperativity in voltage-dependent potassium
channel activation. J. Gen. Physiol. 111:421–439.
16. Smith-Maxwell, C. J., J. L. Ledwell, and R. W. Aldrich. 1998. Role of
the S4 in cooperativity of voltage-dependent potassium channel activa-
tion. J. Gen. Physiol. 111:399–420.
17. Wang, S., S. Liu,., R. L. Rasmusson. 1997. A quantitative analysis of
the activation and inactivation kinetics of hERG expressed in Xenopus
oocytes. J. Physiol. 502:45–60.
18. Bett, G. C. L., Q. Zhou, and R. L. Rasmusson. 2011. Models of hERG
gating. Biophys. J. 101:631–642.
19. Piper, D. R., A. Varghese, ., M. Tristani-Firouzi. 2003. Gating cur-
rents associated with intramembrane charge displacement in hERG po-
tassium channels. Proc. Natl. Acad. Sci. USA. 100:10534–10539.
20. Claydon, T. W., M. Vaid,., D. Fedida. 2007. A direct demonstration
of closed-state inactivation of Kþ channels at low pH. J. Gen. Physiol.
129:437–455.
21. Cheng, Y. M., and T. W. Claydon. 2012. Voltage-dependent gating of
hERG potassium channels. Front. Pharmacol. 3:83.
22. Kiehn, J., A. E. Lacerda, and A. M. Brown. 1999. Pathways of hERG
inactivation. Am. J. Physiol. 277:H199–H210.
23. Clancy, C. E., and Y. Rudy. 2001. Cellular consequences of hERG mu-
tations in the long QT syndrome: precursors to sudden cardiac death.
Cardiovasc. Res. 50:301–313.
24. Clancy, C. E., Z. I. Zhu, and Y. Rudy. 2007. Pharmacogenetics and anti-
arrhythmic drug therapy: a theoretical investigation. Am. J. Physiol.
Heart Circ. Physiol. 292:H66–H75.Biophysical Journal 108(6) 1414–142425. Fink, M., D. Noble,., W. R. Giles. 2008. Contributions of hERG Kþ
current to repolarization of the human ventricular action potential.
Prog. Biophys. Mol. Biol. 96:357–376.
26. Berecki, G., J. G. Zegers, ., A. C. G. van Ginneken. 2005. hERG
channel (dys)function revealed by dynamic action potential clamp
technique. Biophys. J. 88:566–578.
27. Vandenberg, J. I., A. Varghese,., C. L. H. Huang. 2006. Temperature
dependence of human ether-a`-go-go-related gene Kþ currents. Am. J.
Physiol. Cell Physiol. 291:C165–C175.
28. Yang, T., D. J. Snyders, and D. M. Roden. 1997. Rapid inactivation de-
termines the rectification and [Kþ]o dependence of the rapid compo-
nent of the delayed rectifier Kþ current in cardiac cells. Circ. Res.
80:782–789.
29. Brent, R. 1973. Algorithms for Minimization without Derivatives.
Prentice Hall, Upper Saddle River, NJ.
30. Larsen, A. P., B. H. Bentzen, andM. Grunnet. 2010. Differential effects
of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b chan-
nels. Br. J. Pharmacol. 161:614–628.
31. Xu, X., M. Recanatini,., G.-N. Tseng. 2008. Probing the binding sites
and mechanisms of action of two human ether-a`-go-go-related gene
channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea
(NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-
ylamino]-nicotinic acid (PD307243). Mol. Pharmacol. 73:1709–1721.
32. Grunnet, M., J. Abbruzzese,., M. C. Sanguinetti. 2011. Molecular de-
terminants of human ether-a`-go-go-related gene 1 (hERG1) Kþ chan-
nel activation by NS1643. Mol. Pharmacol. 79:1–9.
33. Perry, M., F. B. Sachse, and M. C. Sanguinetti. 2007. Structural basis of
action for a human ether-a`-go-go-related gene 1 potassium channel
activator. Proc. Natl. Acad. Sci. USA. 104:13827–13832.
34. Hansen, R. S., T. G. Diness,., M. Grunnet. 2006. Activation of human
ether-a`-go-go-related gene potassium channels by the diphenylurea
1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol.
Pharmacol. 69:266–277.
35. Hansen, R. S., T. G. Diness,., M. Grunnet. 2006. Biophysical char-
acterization of the new human ether-a`-go-go-related gene channel
opener NS3623 [n-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-n0-(30-tri-
fluoromethylphenyl)urea]. Mol. Pharmacol. 70:1319–1329.
36. Peitersen, T., M. Grunnet,., S.-P. Olesen. 2008. Computational anal-
ysis of the effects of the hERG channel opener NS1643 in a human ven-
tricular cell model. Heart Rhythm. 5:734–741.
37. O’Hara, T., L. Vira´g,., Y. Rudy. 2011. Simulation of the undiseased
human cardiac ventricular action potential: model formulation and
experimental validation. PLOS Comput. Biol. 7:e1002061.
38. Romero, L., B. Trenor, P. C. Yang, J. Saiz, and C. E. Clancy. 2014. In
silico screening of the impact of hERG channel kinetic abnormalities
on channel block and susceptibility to acquired long QT syndrome.
J. Mol. Cell Cardiol. 72:126–137.
